Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:MXCT NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$47.26+1.1%$52.62$44.12▼$78.48$4.56B1.711.81 million shs713,902 shsMXCTMaxCyte$1.05+2.5%$1.19$0.64▼$2.28$111.94M1.471.13 million shs1.15 million shsVRTXVertex Pharmaceuticals$484.47+1.1%$466.62$362.50▼$533.67$122.79B0.291.46 million shs697,016 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+0.41%-0.55%-14.91%-10.24%-27.84%MXCTMaxCyte-5.56%-12.82%-17.74%+16.29%-54.67%VRTXVertex Pharmaceuticals+0.34%-0.31%-2.51%+11.36%+1.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$47.26+1.1%$52.62$44.12▼$78.48$4.56B1.711.81 million shs713,902 shsMXCTMaxCyte$1.05+2.5%$1.19$0.64▼$2.28$111.94M1.471.13 million shs1.15 million shsVRTXVertex Pharmaceuticals$484.47+1.1%$466.62$362.50▼$533.67$122.79B0.291.46 million shs697,016 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+0.41%-0.55%-14.91%-10.24%-27.84%MXCTMaxCyte-5.56%-12.82%-17.74%+16.29%-54.67%VRTXVertex Pharmaceuticals+0.34%-0.31%-2.51%+11.36%+1.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.58Moderate Buy$67.7843.41% UpsideMXCTMaxCyte 2.00Hold$5.00378.47% UpsideVRTXVertex Pharmaceuticals 2.88Moderate Buy$559.6115.51% UpsideCurrent Analyst Ratings BreakdownLatest MXCT, VRTX, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform7/17/2026CRSPCRISPR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026VRTXVertex Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)7/13/2026VRTXVertex Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$545.00 ➝ $585.007/13/2026VRTXVertex Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$542.00 ➝ $560.007/10/2026MXCTMaxCyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/8/2026CRSPCRISPR Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.007/7/2026VRTXVertex Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$543.00 ➝ $570.007/6/2026CRSPCRISPR Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$80.006/30/2026VRTXVertex Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)6/24/2026MXCTMaxCyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$3.51M1,298.64N/AN/A$20.17 per share2.34MXCTMaxCyte$33.03M3.39N/AN/A$1.61 per share0.65VRTXVertex Pharmaceuticals$12.22B10.06$17.84 per share27.16$73.57 per share6.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/10/2026 (Estimated)MXCTMaxCyte-$44.63M-$0.37N/AN/AN/A-121.16%-20.03%-17.14%8/12/2026 (Estimated)VRTXVertex Pharmaceuticals$3.95B$16.8628.7025.732.1535.51%23.86%17.13%8/3/2026 (Estimated)Latest MXCT, VRTX, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026MXCTMaxCyte-$0.12N/AN/AN/A$6.51 millionN/A8/10/2026Q2 2026CRSPCRISPR Therapeutics-$1.1993N/AN/AN/A$7.45 millionN/A8/3/2026Q2 2026VRTXVertex Pharmaceuticals$4.74N/AN/AN/A$3.23 billionN/A5/12/2026Q1 2026MXCTMaxCyte-$0.10-$0.04+$0.06-$0.04$7.28 million$6.22 million5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million5/4/2026Q1 2026VRTXVertex Pharmaceuticals$4.24$4.47+$0.23$4.02$2.99 billion$2.99 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AMXCTMaxCyteN/AN/AN/AN/AN/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR Therapeutics0.3217.9717.96MXCTMaxCyteN/A12.0411.29VRTXVertex PharmaceuticalsN/A3.022.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%MXCTMaxCyte68.81%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics5.20%MXCTMaxCyte4.10%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46096.45 million91.43 millionOptionableMXCTMaxCyte80107.12 million102.73 millionOptionableVRTXVertex Pharmaceuticals6,400253.81 million253.30 millionOptionableMXCT, VRTX, and CRSP HeadlinesRecent News About These CompaniesVertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know2 hours ago | zacks.comThe Manufacturers Life Insurance Company Cuts Position in Vertex Pharmaceuticals Incorporated $VRTXJuly 28 at 6:24 AM | marketbeat.comLazard Asset Management LLC Buys 14,181 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 28 at 5:43 AM | marketbeat.comVertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?July 27 at 12:57 PM | finance.yahoo.comVertex Gears Up to Report Q2 Earnings: What Can Investors Expect?July 27 at 12:57 PM | finance.yahoo.comVertex Gears Up to Report Q2 Earnings: What Can Investors Expect?July 27 at 12:36 PM | zacks.comVertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?July 27 at 11:03 AM | zacks.comVertex Pharmaceuticals (VRTX) Projected to Announce Quarterly Earnings on MondayJuly 27 at 6:25 AM | marketbeat.comOMERS ADMINISTRATION Corp Has $8.39 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTXJuly 27 at 5:44 AM | marketbeat.comLombard Odier Asset Management Switzerland SA Cuts Position in Vertex Pharmaceuticals Incorporated $VRTXJuly 27 at 5:36 AM | marketbeat.comHealthcare of Ontario Pension Plan Trust Fund Purchases 20,523 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 26 at 5:44 AM | marketbeat.comSei Investments Co. Sells 230,797 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 26 at 5:12 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Position Reduced by Cetera Investment AdvisersJuly 26 at 3:51 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Shares Sold by Bank of Nova ScotiaJuly 26 at 3:20 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Shares Sold by Renaissance Technologies LLCJuly 25 at 6:00 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Shares Bought by PNC Financial Services Group Inc.July 25 at 5:03 AM | marketbeat.comArrowstreet Capital Limited Partnership Acquires 45,003 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 25 at 3:07 AM | marketbeat.comVortex Energy Corp. Announces Marketing ProgramJuly 24, 2026 | finance.yahoo.comCaxton Associates LLP Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTXJuly 24, 2026 | marketbeat.comGibbs Wealth Management Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTXJuly 24, 2026 | marketbeat.comCI Investments Inc. Reduces Holdings in Vertex Pharmaceuticals Incorporated $VRTXJuly 24, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026AirJoule Unveils Prime System, Clearing Path to CommercializationBy Thomas Hughes | July 1, 2026Vertex’s Crinetics Deal Balances Growth with Integration RiskBy Chris Markoch | July 8, 2026MXCT, VRTX, and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$47.26 +0.53 (+1.13%) As of 12:43 PM Eastern This is a fair market value price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.MaxCyte NASDAQ:MXCT$1.04 +0.03 (+2.45%) As of 12:43 PM Eastern This is a fair market value price provided by Massive. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Vertex Pharmaceuticals NASDAQ:VRTX$484.47 +5.47 (+1.14%) As of 12:43 PM Eastern This is a fair market value price provided by Massive. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Whirlpool’s Report May Show How Frozen the Housing Market Really Is 3 Stocks Standing Out and 2 Losing Momentum as the Tech Rally Cracks 5 AI Stocks Are Pulling Back—Which Growth Catalysts Still Look Strongest? Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
